Short Interest in Femasys Inc. (NASDAQ:FEMY) Rises By 74.5%

Femasys Inc. (NASDAQ:FEMY) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,150,000 shares, a growth of 74.5% from the February 28th total of 658,900 shares. Approximately 5.9% of the company’s stock are short sold. Based on an average daily volume of 391,100 shares, the days-to-cover ratio is currently 2.9 days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in Femasys by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock worth $238,000 after buying an additional 9,681 shares during the period. XTX Topco Ltd increased its stake in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the period. Virtu Financial LLC purchased a new position in shares of Femasys during the fourth quarter worth $25,000. Jane Street Group LLC acquired a new position in Femasys during the fourth quarter valued at $30,000. Finally, Northern Trust Corp boosted its holdings in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after purchasing an additional 37,675 shares during the last quarter. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Femasys in a research report on Friday.

Femasys Stock Performance

FEMY stock traded down $0.05 during trading on Friday, reaching $1.29. The company had a trading volume of 213,847 shares, compared to its average volume of 244,761. The company has a market cap of $29.54 million, a price-to-earnings ratio of -1.59 and a beta of -2.85. Femasys has a twelve month low of $0.86 and a twelve month high of $1.84. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94. The firm has a 50-day simple moving average of $1.41 and a 200-day simple moving average of $1.22.

Femasys (NASDAQ:FEMY) last released its earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. The firm had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.66 million. As a group, sell-side analysts expect that Femasys will post -0.86 earnings per share for the current year.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.